top of page
CAR-T, produced
inside the body,
begins with delivery.
Conventional CAR-T works,
but it runs into a wall on
COST and ACCESS.
WHY IN VIVO?
1
Long Manufacturing
Long Manufacturing Time
Weeks from cell to infusion.
2
High Cost
High cost
Hundreds of thousands per patient.
3
Pre-Conditioning
Required Chemo
Chemo required before treatment
WHAT WE'RE BUILDING
Delivery is the key.
And the key is LNP.
The success of In Vivo CAR-T comes down to one thing: delivering RNA precisely to T cells. SurgeNex is developing the lipid nanoparticle (LNP) delivery platform that solves this challenge.
TARGETING
T cell–selective delivery
We engineer lipid formulations that home in on T cells, so mRNA reaches only the cells we intend.
ENCAPSULATION
Stable mRNA payload
The CAR mRNA is stably encapsulated, protecting it from degradation during delivery in the body.
SAFETY
Transient, controllable expression
RNA does not integrate into the genome and clears over time, keeping expression controllable and risk low.
MANUFACTURING
Scalable process
An off-the-shelf formulation with no per-patient manufacturing lays the groundwork for production at scale.
HOW IT WORKS
One Injection,
CAR-T Made Inside the Body
A targeted lipid nanoparticle (LNP) delivers CAR mRNA to T cells, which transiently express CAR to attack the tumor.
The Next Chapter of Cell Therapy, Together
We welcome partnership, investment, and press inquiries.
bottom of page